Bio-decontamination in hospitals is significantly more effective using hydrogen peroxide vapour (HPV) technology compared with aerosolised hydrogen peroxide (aHP), according to new research.
In an independent, head-to-head trial of two room decontamination technologies, Bioquell's HPV inactivated 100 per cent of the Geobacillus stearothermophilus biological indicators (BI) using a single cycle.
The aHP system from ASP Glosair (previously branded Sterinis) only managed to inactivate half of the BIs despite the use of three back to back cycles.
The team of research doctors, based at Lund University Malmo also demonstrated further performance benefits when using the Bioquell Q-10 HPV equipment.
It reached higher peak hydrogen peroxide room concentrations (338ppm versus 160ppm) and achieved a shorter cycle time (three hours versus 3.5 hours).
The trial was set up following calls two years ago for head-to-head bio-decontamination studies by environmental microbiology expert, Dr John Boyce.
The Malmo team built a full-scale mock-up of an isolation room to run the trial.
This mimicked the new Infectious Disease facility at Skane University Hospital (SUS).
In the trial, only one Bioquell Q-10 suite and two ASP Glosair (Sterinis) aHP machines were used.
The advanced hydrogen peroxide vapour (HPV) technology used by Bioquell technicians bio-deactivates a range of animal and human pathogens.
It is a safe and environmentally friendly process of high level room and equipment decontamination.
